Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China

Detalhes bibliográficos
Autor(a) principal: Wu, Qilin
Data de Publicação: 2022
Outros Autores: Wang, Chang, Jing, Qinlong, Lu, Jianyun, Liang, Boheng, Liu, Lan, Wu, Jinyi, Yu, Qing, Deng, Xilong, Zhang, Zhoubin
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista do Instituto de Medicina Tropical de São Paulo
Texto Completo: https://www.revistas.usp.br/rimtsp/article/view/197664
Resumo: The B.1.617.2 (Delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a new increment in cases across the globe. We conducted a prospective follow-up of COVID-19 cases to explore the recurrence and potential propagation risk of the Delta variant and discuss potential explanations for the infection recurrence. A prospective, non-interventional follow-up of discharged patients who had SARS-CoV-2 infections by the Delta variant in Guangdong, China, from May 2021 to June 2021 was conducted. The subjects were asked to complete a physical health examination and undergo nucleic acid testing and antibody detection for the laboratory diagnosis of COVID-19. In total, 20.33% (25/123) of patients exhibited recurrent positive results after discharge. All patients with infection recurrence were asymptomatic and showed no abnormalities in the pulmonary computed tomography. The time from discharge to the recurrent positive testing was usually between 1-33 days, with a mean time of 9.36 days. The cycle threshold from the real-time polymerase chain reaction assay that detected the recurrence of positivity ranged from 27.48 to 39.00, with an average of 35.30. The proportion of vaccination in the non-recurrent group was higher than that in the recurrently positive group (26% vs. 4%; χ2 = 7.902; P < 0.05). Two months after discharge, the most common symptom was hair loss and 59.6% of patients had no long-term symptoms at all. It is possible for the Delta variant SARS-CoV-2 patients after discharge to show recurrent positive results of nucleic acid detection; however, there is a low risk of continuous community transmission. Both, the physical and mental quality of life of discharged patients were significantly affected. Our results suggest that it makes sense to implement mass vaccination against the Delta variant of SARS-CoV-2.
id IMT-1_3b276fc20e8b917b6edcc33b1a54ae96
oai_identifier_str oai:revistas.usp.br:article/197664
network_acronym_str IMT-1
network_name_str Revista do Instituto de Medicina Tropical de São Paulo
repository_id_str
spelling Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, ChinaCOVID-19SARS-CoV-2Follow-up surveyDelta variantThe B.1.617.2 (Delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a new increment in cases across the globe. We conducted a prospective follow-up of COVID-19 cases to explore the recurrence and potential propagation risk of the Delta variant and discuss potential explanations for the infection recurrence. A prospective, non-interventional follow-up of discharged patients who had SARS-CoV-2 infections by the Delta variant in Guangdong, China, from May 2021 to June 2021 was conducted. The subjects were asked to complete a physical health examination and undergo nucleic acid testing and antibody detection for the laboratory diagnosis of COVID-19. In total, 20.33% (25/123) of patients exhibited recurrent positive results after discharge. All patients with infection recurrence were asymptomatic and showed no abnormalities in the pulmonary computed tomography. The time from discharge to the recurrent positive testing was usually between 1-33 days, with a mean time of 9.36 days. The cycle threshold from the real-time polymerase chain reaction assay that detected the recurrence of positivity ranged from 27.48 to 39.00, with an average of 35.30. The proportion of vaccination in the non-recurrent group was higher than that in the recurrently positive group (26% vs. 4%; χ2 = 7.902; P < 0.05). Two months after discharge, the most common symptom was hair loss and 59.6% of patients had no long-term symptoms at all. It is possible for the Delta variant SARS-CoV-2 patients after discharge to show recurrent positive results of nucleic acid detection; however, there is a low risk of continuous community transmission. Both, the physical and mental quality of life of discharged patients were significantly affected. Our results suggest that it makes sense to implement mass vaccination against the Delta variant of SARS-CoV-2.Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo2022-05-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/rimtsp/article/view/19766410.1590/S1678-9946202264031Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e31Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e31Revista do Instituto de Medicina Tropical de São Paulo; v. 64 (2022); e311678-99460036-4665reponame:Revista do Instituto de Medicina Tropical de São Pauloinstname:Instituto de Medicina Tropical (IMT)instacron:IMTenghttps://www.revistas.usp.br/rimtsp/article/view/197664/181898Copyright (c) 2022 Qilin Wu, Chang Wang, Qinlong Jing, Jianyun Lu, Boheng Liang, Lan Liu, Jinyi Wu, Qing Yu, Xilong Deng, Zhoubin Zhanghttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessWu, Qilin Wang, Chang Jing, Qinlong Lu, Jianyun Liang, Boheng Liu, Lan Wu, Jinyi Yu, Qing Deng, Xilong Zhang, Zhoubin 2022-10-10T13:01:46Zoai:revistas.usp.br:article/197664Revistahttp://www.revistas.usp.br/rimtsp/indexPUBhttps://www.revistas.usp.br/rimtsp/oai||revimtsp@usp.br1678-99460036-4665opendoar:2022-12-13T16:53:16.923159Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)true
dc.title.none.fl_str_mv Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
title Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
spellingShingle Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
Wu, Qilin
COVID-19
SARS-CoV-2
Follow-up survey
Delta variant
title_short Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
title_full Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
title_fullStr Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
title_full_unstemmed Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
title_sort Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
author Wu, Qilin
author_facet Wu, Qilin
Wang, Chang
Jing, Qinlong
Lu, Jianyun
Liang, Boheng
Liu, Lan
Wu, Jinyi
Yu, Qing
Deng, Xilong
Zhang, Zhoubin
author_role author
author2 Wang, Chang
Jing, Qinlong
Lu, Jianyun
Liang, Boheng
Liu, Lan
Wu, Jinyi
Yu, Qing
Deng, Xilong
Zhang, Zhoubin
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Wu, Qilin
Wang, Chang
Jing, Qinlong
Lu, Jianyun
Liang, Boheng
Liu, Lan
Wu, Jinyi
Yu, Qing
Deng, Xilong
Zhang, Zhoubin
dc.subject.por.fl_str_mv COVID-19
SARS-CoV-2
Follow-up survey
Delta variant
topic COVID-19
SARS-CoV-2
Follow-up survey
Delta variant
description The B.1.617.2 (Delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a new increment in cases across the globe. We conducted a prospective follow-up of COVID-19 cases to explore the recurrence and potential propagation risk of the Delta variant and discuss potential explanations for the infection recurrence. A prospective, non-interventional follow-up of discharged patients who had SARS-CoV-2 infections by the Delta variant in Guangdong, China, from May 2021 to June 2021 was conducted. The subjects were asked to complete a physical health examination and undergo nucleic acid testing and antibody detection for the laboratory diagnosis of COVID-19. In total, 20.33% (25/123) of patients exhibited recurrent positive results after discharge. All patients with infection recurrence were asymptomatic and showed no abnormalities in the pulmonary computed tomography. The time from discharge to the recurrent positive testing was usually between 1-33 days, with a mean time of 9.36 days. The cycle threshold from the real-time polymerase chain reaction assay that detected the recurrence of positivity ranged from 27.48 to 39.00, with an average of 35.30. The proportion of vaccination in the non-recurrent group was higher than that in the recurrently positive group (26% vs. 4%; χ2 = 7.902; P < 0.05). Two months after discharge, the most common symptom was hair loss and 59.6% of patients had no long-term symptoms at all. It is possible for the Delta variant SARS-CoV-2 patients after discharge to show recurrent positive results of nucleic acid detection; however, there is a low risk of continuous community transmission. Both, the physical and mental quality of life of discharged patients were significantly affected. Our results suggest that it makes sense to implement mass vaccination against the Delta variant of SARS-CoV-2.
publishDate 2022
dc.date.none.fl_str_mv 2022-05-16
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/rimtsp/article/view/197664
10.1590/S1678-9946202264031
url https://www.revistas.usp.br/rimtsp/article/view/197664
identifier_str_mv 10.1590/S1678-9946202264031
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/rimtsp/article/view/197664/181898
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo
publisher.none.fl_str_mv Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo
dc.source.none.fl_str_mv Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e31
Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e31
Revista do Instituto de Medicina Tropical de São Paulo; v. 64 (2022); e31
1678-9946
0036-4665
reponame:Revista do Instituto de Medicina Tropical de São Paulo
instname:Instituto de Medicina Tropical (IMT)
instacron:IMT
instname_str Instituto de Medicina Tropical (IMT)
instacron_str IMT
institution IMT
reponame_str Revista do Instituto de Medicina Tropical de São Paulo
collection Revista do Instituto de Medicina Tropical de São Paulo
repository.name.fl_str_mv Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)
repository.mail.fl_str_mv ||revimtsp@usp.br
_version_ 1798951655006273536